Search

everythinglearnresearchcommunity

for

Search:↓

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.

Oral minoxidil can cause skin issues like redness and bumps. The user saw no hair improvement with oral minoxidil but noticed increased facial hair.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

Switching from oral minoxidil back to topical due to heart issues and palpitations. Users discuss experiences with minoxidil and finasteride, with mixed results and concerns about side effects.

Oral minoxidil can cause severe side effects, including heart issues, even at low doses. Users suggest starting with a lower dose or using topical treatments to minimize risks.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

The user experienced hair thinning, possibly due to long COVID and prediabetes, and saw regrowth after dietary changes and using biotin shampoo. They are taking vitamins and noticed significant hair regrowth, especially at the widow's peak.

The user is using oral finasteride, topical minoxidil, and tretinoin to treat hair loss. After two months, there is noticeable thickening and maintenance of the hairline.

The conversation discusses severe hair shedding and thinning, with the original poster using finasteride, oral minoxidil, and other supplements without improvement. The discussion highlights the possibility of telogen effluvium and the importance of addressing potential underlying health issues, such as stress and gut health, rather than assuming diffuse unpatterned alopecia (DUPA).

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

The user is experiencing diffuse thinning despite using oral minoxidil (3mg), dutasteride (0.5mg), microneedling, scalp massaging, and vitamins. Suggestions include increasing the minoxidil dose, checking for scalp conditions, and continuing current treatments.

People are humorously discussing unconventional and extreme methods of using hair loss treatments like finasteride and minoxidil, including vaping, snorting, and injecting. The conversation is filled with jokes and sarcasm about these methods.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

People with diffuse thinning and retrograde hair loss are discussing treatments like finasteride, minoxidil, and dutasteride, with some reporting improvements and others experiencing issues like scalp inflammation and increased sebum. Suggestions include addressing scalp inflammation, considering gut health, and possibly using topical antiandrogens or micro-needling.

The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

Avoid home-compounding topical minoxidil due to potential risks and complications. Use proper equipment and techniques to prevent aerosolization and ensure effective dissolution.

The conversation discusses using minoxidil and finasteride for hair loss, with concerns about absorption and considering adding tretinoin for better results. Microneedling is suggested as a method to improve absorption, with varying depths and frequencies recommended.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

The user is considering topical Saw Palmetto or Pumpkin Seed Oil due to sensitivity to finasteride and cost issues. They also use dermastamping for Minoxidil absorption and seek advice on timing to avoid systemic absorption.